A ROS1 mutation, more precisely a ROS1 gene fusion, is a chromosomal rearrangement in which the ROS1 gene gets spliced together with another gene, producing a hybrid protein that is permanently switched on and drives cancer cell growth. The ROS1 gene normally encodes a receptor on the surface of cells, and its exact role in healthy human tissue remains surprisingly unclear. But when a piece of ROS1 fuses with the wrong partner gene, the resulting protein signals nonstop for cells to divide, forming tumors. ROS1 fusions are best known for their role in a subset of non-small-cell lung cancers, where they show up in roughly 1 to 2 percent of all cases, and the good news is that several targeted drugs can block the rogue protein effectively.
Where ROS1 Fusions Occur
ROS1 fusions are overwhelmingly associated with lung adenocarcinoma, the most common subtype of non-small-cell lung cancer (NSCLC). A meta-analysis pooling data from 37 studies found ROS1 rearrangements in about 2.5 percent of lung adenocarcinomas, while the rate in non-adenocarcinoma lung tumors was far lower.1PubMed Central. Clinical characteristics of patients with ROS1 gene rearrangement in non-small cell lung cancer: a meta-analysis That sounds small, but given how many people are diagnosed with lung cancer globally, a 2 percent slice still translates to thousands of patients each year.
Beyond the lungs, ROS1 fusions have been identified in a range of other cancers in both adults and children. A review in Nature Reviews Clinical Oncology described ROS1 fusions as driving a “diverse range of cancers in adult and paediatric patients,” though regulatory approvals for targeted drugs have so far been granted only for ROS1-positive NSCLC.2PubMed Central. ROS1-dependent cancers – biology, diagnostics and therapeutics Histology-agnostic approvals that would cover any tumor type harboring a ROS1 fusion have not yet been granted, which means patients with ROS1-driven cancers outside the lung often rely on off-label use or clinical trials.
Who Is Most Likely to Have a ROS1 Fusion
ROS1-positive lung cancer has a distinct demographic fingerprint. Pooled analyses show a significantly higher rate among women, people who have never smoked, and patients with advanced-stage disease at the time of diagnosis.3PubMed Central. Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis If you are a never-smoker diagnosed with lung adenocarcinoma, ROS1 testing is especially important because you are more than three times as likely to carry the fusion compared to someone with a smoking history. Patients are also typically younger than the average lung cancer population, a pattern shared with ALK-rearranged lung cancer, which behaves in many analogous ways.
This profile matters practically. If you fit these demographics and your initial molecular tests come back negative for EGFR mutations and ALK rearrangements, pushing for ROS1 testing could change your treatment entirely. Current guidelines from major oncology organizations recommend testing all advanced NSCLC patients for ROS1, but in busy clinical settings, it can still be overlooked.
How the Fusion Drives Cancer
In a healthy cell, the ROS1 protein sits on the cell surface waiting for a signal before it activates. A fusion scrambles that system. When part of another gene gets joined to ROS1’s active region, the resulting chimeric protein no longer needs an external signal. It is locked in the “on” position, constantly telling the cell to grow and survive. The specific partner gene matters: the most common fusion partner, CD74, accounts for about half of all cases, followed by EZR, SDC4, and TPM3.4PubMed Central. Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to Crizotinib
Research has shown that different fusion partners actually place the chimeric protein in different locations within the cell, which changes the downstream signaling that gets activated. For example, fusions like SDC4-ROS1 and SLC34A2-ROS1 end up on endosomes (small compartments involved in sorting cell cargo), where they strongly activate the MAPK growth-signaling pathway. CD74-ROS1 variants, by contrast, tend to sit in the endoplasmic reticulum and show weaker MAPK activation. In lab experiments, physically relocating CD74-ROS1 from the endoplasmic reticulum to endosomes restored MAPK signaling.5Cancer Research. Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins The practical takeaway is that not all ROS1 fusions are created equal, and the identity of the fusion partner can influence how aggressively the cancer behaves and how it responds to drugs.
How ROS1 Fusions Are Detected
There are several ways to detect a ROS1 rearrangement. Fluorescence in situ hybridization (FISH) has long been the standard lab test: it uses fluorescent probes to physically see the gene rearrangement under a microscope. Immunohistochemistry (IHC), a simpler and cheaper staining method, can screen for the ROS1 protein on tissue slides. When measured against FISH as the gold standard, IHC achieved 100 percent sensitivity and close to 98 percent specificity, making it a strong initial screen.6OncoTargets and Therapy. Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features Most institutions use IHC as the first step and confirm positive or borderline results with FISH or next-generation sequencing (NGS).
NGS-based panels are increasingly the go-to approach because they test for ROS1 fusions alongside dozens of other actionable mutations in a single run, saving time and tissue. Beyond tissue biopsies, liquid biopsy—drawing a blood sample and analyzing circulating tumor DNA—has emerged as a complement. Amplicon-based sequencing of blood samples can detect ROS1 fusions in patients who have not yet started treatment and can identify resistance mutations in patients already on targeted therapy.7PubMed Central. Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer Serial blood draws during treatment can also track whether the tumor’s DNA profile is shifting before a scan shows anything has changed.8PubMed Central. Serial Cell-Free DNA Sequencing in ROS1 Fusion-Positive Lung Cancers During Treatment With Entrectinib
Targeted Drugs for ROS1-Positive Lung Cancer
The arrival of targeted therapies fundamentally changed the outlook for patients with ROS1-positive NSCLC. Crizotinib, originally developed to block ALK and MET, turned out to work against ROS1 as well and became the first drug approved for this indication. It is still considered the standard first-line treatment.9PubMed Central. Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies In the pivotal trial, about 72 percent of patients had their tumors shrink meaningfully, and the median time before the cancer started growing again was over 19 months.10PubMed Central. Crizotinib in ROS1-rearranged non-small-cell lung cancer A larger study in East Asian patients reported a similar response rate and a median progression-free survival of nearly 16 months.11PubMed. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer
One important limitation of crizotinib is its poor penetration into the brain. Up to about a third of patients with ROS1-positive NSCLC have brain metastases at the time of diagnosis, and crizotinib does not cross the blood-brain barrier well enough to control them reliably. Entrectinib was designed with this problem in mind. An integrated analysis of three trials showed that 77 percent of evaluable patients responded, with a median duration of response approaching 25 months, and the drug was effective in the central nervous system.12The Lancet Oncology. Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials Both crizotinib and entrectinib are now approved options in the first-line setting, and the choice between them often hinges on whether brain metastases are present.
When Targeted Drugs Stop Working
Eventually, most ROS1-positive tumors develop resistance to whichever drug they are on. Resistance falls into two broad categories. “On-target” resistance means the cancer picks up a new mutation within the ROS1 gene itself, changing the shape of the protein just enough that the drug no longer fits. “Off-target” resistance means other genes in the cancer cell take over the growth-signaling job, bypassing ROS1 entirely.
Among patients who progressed on crizotinib, on-target ROS1 mutations were found in about 38 percent of cases, rising to around 46 percent in patients who progressed on lorlatinib, a next-generation inhibitor. The single most common resistance mutation, G2032R, appeared in roughly a third of cases overall.13Clinical Cancer Research. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer The G2032R mutation is a stubborn problem; lorlatinib, despite being more potent against many ROS1 mutations, has essentially no activity against it.14PubMed Central. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy
Off-target resistance adds another layer of complexity. In one detailed study, about 14 percent of post-crizotinib samples showed off-target alterations, including mutations in KRAS, MET, and PIK3CA. Some patients even carried both on-target and off-target resistance mutations simultaneously, or multiple off-target mutations at once.15Clinical Chemistry. Mechanisms of Resistance to Tyrosine Kinase Inhibitors in ROS1 Fusion-Positive Nonsmall Cell Lung Cancer These complex resistance profiles underline why repeat biopsies or liquid biopsies at progression are so valuable: the treatment that comes next depends entirely on what has changed inside the tumor.
Next-Generation Drugs and the G2032R Problem
Repotrectinib is the most prominent example of a new generation of ROS1 inhibitors designed to overcome resistance. In a clinical trial, patients whose cancer had progressed on one prior ROS1 inhibitor and had not received chemotherapy had a 38 percent response rate, with responses lasting a median of about 15 months. Among patients specifically harboring the G2032R mutation, the response rate was 59 percent.16PubMed Central. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer That marked a significant advance against a mutation that had been considered essentially untreatable with existing targeted agents.
Researchers have also investigated experimental compounds. DS-6051b, for instance, demonstrated lab activity against the G2032R mutation and several other crizotinib-resistant mutations, though it did not work against every variant.17Nature Communications. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models No single drug covers all possible resistance mutations, which is why the treatment sequencing in ROS1-positive cancer has become a chess game: understanding which resistance mutation appeared dictates which drug might work next.
Why Immunotherapy Alone Does Not Work Well Here
Checkpoint immunotherapy has transformed treatment for many types of lung cancer, but ROS1-positive tumors are not among the big beneficiaries. Single-agent immunotherapy with PD-1 or PD-L1 inhibitors shows only modest activity, with response rates in the range of 8 to 17 percent.18The Oncologist. Advances and future directions in ROS1 fusion-positive lung cancer 19PubMed Central. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis This pattern is shared with other oncogene-driven cancers like ALK-positive and EGFR-mutant NSCLC, where the tumors tend to have low mutation burden and relatively “cold” immune environments.
Combining immunotherapy with chemotherapy shows somewhat better results, but targeted inhibitors still outperform immunotherapy in the first-line setting for ROS1-positive patients by a wide margin. The practical implication: if your tumor is ROS1-positive, immunotherapy is not your best first move. Targeted therapy is. Immunotherapy or chemo-immunotherapy combinations generally enter the picture later, after targeted options have been exhausted.
The Fusion Partner Can Influence Drug Response
Most discussions about ROS1-positive cancer treat all fusions as interchangeable for treatment purposes. In many cases, the clinical outcomes on drugs like crizotinib are similar regardless of which partner gene is involved. But emerging evidence suggests that certain fusion variants respond less favorably. A study of 210 patients found that those with “long” variants of CD74-ROS1 or SLC34A2-ROS1 fusions—versions that include part of the transmembrane region—had significantly shorter progression-free survival on crizotinib, regardless of whether they also carried TP53 mutations.20PubMed. CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations
This is a relatively new area of research, and most clinical trials have not stratified results by fusion partner variant. As more detailed molecular data become available, the identity of the specific fusion breakpoint may start to influence which drug a patient receives first, pushing treatment toward a more personalized approach even within the already small ROS1-positive population.
ROS1 and ALK Are Structural Relatives
If you have read about ALK-positive lung cancer, you may notice a lot of overlap with the ROS1 story, and that is not a coincidence. The two proteins are structurally related, with shared features in their active regions. Researchers have exploited this resemblance to build predictive models: by studying how certain resistance mutations in one kinase respond to drugs, they can anticipate how analogous mutations in the other will behave. One research group showed that a ROS1 resistance mutation and an ALK resistance mutation at structurally equivalent positions had similar drug sensitivity profiles, then used that analogy to forecast how future ROS1 resistance mutations might respond to various inhibitors.21Clinical Cancer Research. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers
This structural kinship is also why several drugs—crizotinib, lorlatinib, and others—are active against both ALK and ROS1 fusions. Drug development in the ALK space is further along, with more generations of inhibitors available, so insights from ALK resistance frequently inform the ROS1 treatment landscape. When a patient with ROS1-positive cancer develops an unusual resistance mutation that has not been studied in a ROS1 context, clinicians may look to the ALK literature for clues about which drug to try next.
Beyond Fusions: ROS1 Point Mutations
Gene fusions are the headline story for ROS1, but researchers have recently begun exploring whether standalone point mutations in the ROS1 gene—changes that do not involve fusing with another gene—can also drive cancer. Lab experiments identified several ROS1 missense mutations with cancer-promoting potential. The most active was a mutation called D2113N, which cranked up the ROS1 protein’s signaling activity by more than 50-fold compared to the normal version. Cells carrying this mutation grew faster, formed tumors in mice, and, critically, were sensitive to existing ROS1-targeted drugs like crizotinib, lorlatinib, and NVL-520.22PubMed Central. Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors
This finding is early-stage and has not yet changed clinical practice, but it matters for two reasons. First, patients whose tumors carry one of these activating point mutations would not be flagged by the standard fusion-detection assays; they would need broader genomic testing to identify the alteration. Second, if these mutations respond to the same drugs used for ROS1 fusions, a larger pool of patients could eventually benefit from targeted therapy. How many patients carry such mutations in the real world remains an open question.
The Role of Patient Advocacy in ROS1 Research
Because ROS1-positive cancer is rare, research has historically moved more slowly than it has for common mutations like EGFR. Patient-led organizations have played an unusual role in filling gaps. The ROS1ders, a patient advocacy group, has supported basic science by donating tissue samples that allowed researchers to create new ROS1-specific cell lines for laboratory study.23Clinical Cancer Research. Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer Cell lines are the workhorses of preclinical drug testing, and having ones that faithfully represent ROS1-driven tumors is essential for screening new compounds and understanding resistance.
For patients and families navigating a ROS1 diagnosis, connecting with a group like this can offer more than emotional support. Rare-cancer advocacy organizations often maintain up-to-date information on clinical trials, facilitate access to specialized oncologists who have treated enough ROS1 cases to have real expertise, and serve as informal bridges between the patient community and the researchers studying their disease. In a field where a general oncologist might see only a handful of ROS1-positive patients in a career, that concentrated knowledge can be the difference between a standard treatment plan and one informed by the latest evidence.